Arabic Arabic English English French French German German
dark

Navidea Biopharmaceuticals Announces End-of-Phase 2 Type B Meeting Request Granted by the FDA to Discuss Ongoing Clinical Program in Rheumatoid Arthritis

Navidea Biopharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (“FDA”) has granted the Company’s request for an End-of-Phase 2 Type B meeting to discuss its ongoing program in Rheumatoid Arthritis (“RA”) and advancement to the pivotal Phase 3 trial. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

DiaMedica Therapeutics Elects Two Industry Veterans to Its Board of Directors

Next Post

Saama Announces Support for AWS Health Initiative

Related Posts
Total
0
Share